Opendata, web and dolomites

TRAIN-HEART SIGNED

TRAIN-HEART

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRAIN-HEART project word cloud

Explore the words cloud of the TRAIN-HEART project. It provides you a very rough idea of what is the project "TRAIN-HEART" about.

treatment    academic    arrangements    companies    15    pathogenesis    accelerate    innovation    league    science    teams    biotech    efficacy    scientific    strategies    act    treating    hold    brings    individual    therapeutic    curative    exception    complemented    molecules    cardiac    harness    edge    rna    transplantation    rnas    remodelling    regulators    chronic    encourage    tolerability    momentous    network    excellent    coding    genomics    chemically    employability    oligonucleotides    transferable    functional    expand    stress    insights    content    keen    biology    international    cardiovascular    specificity    training    underlying    therapy    disease    supervision    clinic    critical    tissue    horizons    therapeutics    active    therapies    minded    synergies    innovative    detrimental    drug    phd    right    substantially    promise    heart    proposition    generation    ischemic    train    skills    cutting    causes    multidisciplinary    provides    intersectoral    combination    modified    envisioned    trainings    micrornas    specialised    fellows    entrepreneurial   

Project "TRAIN-HEART" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙940˙388 €
 EC max contribution 3˙940˙388 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2023-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 531˙239.00
2    KING'S COLLEGE LONDON UK (LONDON) participant 606˙345.00
3    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) participant 522˙999.00
4    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 505˙576.00
5    UNIVERSIDADE DO PORTO PT (PORTO) participant 475˙440.00
6    UNIVERSITE LYON 1 CLAUDE BERNARD FR (VILLEURBANNE CEDEX) participant 274˙802.00
7    MIRABILIS THERAPEUTICS BV NL (MAASTRICHT) participant 265˙619.00
8    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 252˙788.00
9    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 252˙788.00
10    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 252˙788.00
11    ACCELERO BIOANALYTICS GMBH DE (BERLIN) partner 0.00
12    DESCIN BV NL (Vinkeveen) partner 0.00
13    EHT TECHNOLOGIES GMBH DE (HAMBURG) partner 0.00
14    HARTERAAD NL (S-GRAVENHAGE) partner 0.00
15    KANEKA EUROGENTEC BE (SERAING) partner 0.00
16    SOCIETE EUROPEENNE DE CARDIOLOGIE FR (BIOT SOPHIA ANTIPOLIS) partner 0.00

Map

 Project objective

TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics for the treatment of ischemic heart failure. Under chronic cardiac stress, non-coding RNAs, in particular microRNAs and long non-coding RNAs, act as critical regulators of cardiac tissue remodelling. Innovative therapies targeting these RNA molecules hold great promise in treating the underlying causes of ischemic heart failure. With the exception of heart transplantation, there is no curative therapy available for this detrimental disease. Given the challenges related to delivery, specificity and tolerability of RNA therapeutics, developments in chemically modified oligonucleotides and drug delivery strategies are growing substantially. TRAIN-HEART’s proposition is to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems. TRAIN-HEART provides such training in a European network of top-level academic teams and (biotech) companies active in the fields of cardiovascular biology, functional genomics and drug development. All individual research projects demonstrate multidisciplinary content and supervision arrangements, momentous intersectoral exchanges and international synergies. These PhD programmes are complemented with the right combination of specialised research- and transferable skills trainings to encourage excellent science, innovation and long-term employability. The TRAIN-HEART fellows are envisioned to become entrepreneurial researchers who are keen to bring cutting-edge scientific concepts in RNA therapeutics to the clinic.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRAIN-HEART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRAIN-HEART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

i-CONN (2019)

Interdisciplinary connectivity: Understanding and managing complex systems using connectivity science

Read More  

NanoCarb (2018)

Glyco-Nanoparticles for Applications in Advance Nanomedicine

Read More  

Shape-IT (2019)

Supporting the interaction of Humans and Automated vehicles: Preparing for the EnvIronment of Tomorrow

Read More